BioCatalystWatch
TELOWorkspace / TELO / OverviewCompany library
Telomir Pharmaceuticals, Inc. logo

Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (TELO)

Website

Price
Market cap
Next catalystClinical initiation targeted for Q1 2027; anticipated timing subject to changeTelomir-Zn — planned Phase 1/2 monotherapy study · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

Intracellular iron (Fe2+/Fe3+) × Intracellular copper

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Telomir-1 (Telomir-Zn)

Intracellular iron (Fe2+/Fe3+) × Intracellular copper

PreINDP1P2P3FilingApproved
Telomir-1 (Telomir-Zn)

Intracellular iron (Fe2+/Fe3+) × Intracellular copper

Telomir-Ag2

Bacterial DNA × Bacterial proteins

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

TELO PR & News

PR & News

TELO SEC archive